A Study of Enlicitide Decanoate (MK-0616) and Semaglutide in Healthy Adult Participants (MK-0616-023)

NCT06699329 · Completed

Last updated 2026-05-28

This clinical trial is testing the safety and effects of two diabetes medications, enlicitide decanoate and semaglutide, in healthy adult participants.

Status Completed The study has finished.

Phase Phase 1 Checks safety and dosing in a small group.

Type Interventional (clinical trial)

Design open-label (no blinding) basic-science study

Participants 38 people

Who can join Ages 19–55 · all sexes Healthy volunteers accepted.

Timeline Started 2024-01 · est. completion 2024-05

Where 1 site · United States

What this study is testing ClinicalTrials.gov NCT06699329 ↗

Description as written by the study sponsor.

The goal of this study is to learn what happens in a person's body over time when they take enlicitide decanoate and semaglutide alone or at the same time. Enlicitide decanoate is a new medicine that lowers the amount of cholesterol in a person's blood. Semaglutide is a drug used to treat type 2 diabetes. Researchers want to learn what happens to the amount of semaglutide and enlicitide decanoate in a person's blood when each drug is taken alone and when they are taken together.

Treatments tested

Enlicitide Decanoate also known as MK-0616 Drug

multiple doses, oral tablet
Semaglutide also known as Rybelsus Drug

multiple doses, oral tablet

Main thing measured	Area Under the Concentration-Time Curve from Time 0 to 24 hours (AUC0-24hrs) of Enlicitide Decanoate
Sponsor	Merck Sharp & Dohme LLC
Conditions studied	Healthy
GLP-1 drugs	semaglutide

Full protocol, eligibility, and contacts on ClinicalTrials.gov NCT06699329 ↗